Given that glaucarubin readily induces DNA damage in MCPyV-positive MCCs such as MKL-1, MKL-2, PeTa, and BroLi, but failed to inhibit BCL-2 in any of the cell types tested, we reasoned that BCL-2 activity in these MCPyV-positive MCC cells could confer resistance to complete loss of viability after glaucarubin treatment. The gene discussed is MRTFA; the disease is Merkel cell skin cancer.